Gong Xin's Half-Year Revenue Increased by 33 Percent, Cancer Drug Patent Approved in the US

Taiwanese biotechnology company Gong Xin-KY announced that it reached record revenues in the first half of the year, with an annual increase of 33…

The key patent approvals obtained in the European and American markets have a significant share in this remarkable growth of the company.